Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis
Completed · Phase 4
Conditions studied: Plaque Psoriasis
In brief
The purpose of this study is to evaluate Halobetasol Propionate (HBP) foam, 0.05% in subjects aged 12 through less than 18 years with plaque psoriasis in order to check the safety, the potential to suppress the adrenal glands and the degree to which the drug is absorbed into the bloodstream.
Key facts
- Study ID
- NCT03992261
- Run by
- Mayne Pharma International Pty Ltd
- People needed
- 24
- Starts
- 2019-06-14
- Expected to finish
- 2019-12-30
- Last updated by the study team
- 2023-07-06
Who can join
Age: 12 and older, up to 17. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Investigative Site 2 — Hialeah, Florida, United States
- Investigative Site 1 — Saint Joseph, Missouri, United States
- Investigative Site 9 — Batumi, Georgia
- Investigative Site 10 — Tbilisi, Georgia
- Investigative Site 11 — Tbilisi, Georgia
- Investigative Site 3 — Krakow, Poland
- Investigative Site 5 — Tarnów, Poland
- Investigative Site 4 — Warsaw, Poland
- Investigative Site 8 — Rivne, Ukraine
- Investigative Site 6 — Uzhhorod, Ukraine
- Investigative Site 7 — Zaporizhzhya, Ukraine
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.